Tirzepatide Oral Disintegrating Tablet (ODT) is a dual glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist used to support weight management.

Tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, two hormones involved in blood sugar regulation. By engaging these pathways, tirzepatide enhances insulin production and secretion from pancreatic beta cells in response to elevated blood glucose levels, supporting glycemic control after meals.
Through its dual activity, tirzepatide influences glucagon release from alpha cells, decreasing it through GLP-1 signaling and modulating it through GIP. It also slows gastric emptying, reduces gastrointestinal motility, and enhances satiety signals in the brain, leading to a reduction in appetite. These effects support the body’s ability to regulate glucose and maintain metabolic balance.
In fat tissue, tirzepatide plays a role in metabolic regulation by supporting fat breakdown and influencing how the body stores and utilizes lipids. It helps promote a healthier metabolic profile through its combined hormonal actions.

Tirzepatide is not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those diagnosed with multiple endocrine neoplasia syndrome type 2 (MEN 2).
This medication is also contraindicated in individuals with known hypersensitivity to tirzepatide or any of its components. Use is not advised in those who have previously experienced angioedema or anaphylaxis to tirzepatide or similar GLP-1 receptor agonists.
Tirzepatide is not intended for use in individuals with type 1 diabetes.
Caution is advised in individuals with gallbladder disease or diabetic retinopathy.

GLP-1 Agonists
Tirzepatide should not be used together with other GLP-1 receptor agonists, such as semaglutide or liraglutide, as combining these medications is not recommended.
Gastric Emptying
Tirzepatide may delay gastric emptying, which can affect the absorption of oral medications. Caution is advised when prescribing tirzepatide alongside drugs with a narrow therapeutic index or those that require consistent absorption. This is especially important in individuals with conditions like gastroparesis.
Oral Contraceptives
Delayed gastric emptying may interfere with the absorption of oral contraceptives. Individuals using birth control pills should consider an alternative or additional barrier method of contraception for at least four weeks after starting tirzepatide or increasing the dose.
Insulin and Secretagogues
When used with insulin or sulfonylureas, tirzepatide may increase the risk of hypoglycemia. Dose adjustments and close monitoring of blood glucose may be necessary.
NOTE: This is not a comprehensive list of medications that may interact with tirzepatide. For a complete understanding of potential interactions, please consult a healthcare professional or specialized resource.

Hypoglycemia
When used with other blood sugar-lowering medications such as insulin or sulfonylureas, tirzepatide may increase the risk of hypoglycemia. Blood glucose levels should be monitored closely, and adjustments to other medications may be necessary.
Gastrointestinal Side Effects
Common gastrointestinal side effects include nausea, vomiting, diarrhea, and constipation. These symptoms are more likely to occur during the early stages of treatment or following a dose increase. They often improve as the body adjusts to the medication.
Pancreatitis
Acute pancreatitis has been reported with GLP-1 receptor agonists. Individuals should be aware of symptoms such as severe and persistent abdominal pain, especially if it radiates to the back or is accompanied by vomiting.
Diabetic Retinopathy
Rapid improvements in blood glucose control may temporarily worsen existing diabetic retinopathy. Individuals with a history of diabetic eye disease should be monitored for changes in vision.
Hepatobiliary Effects
Gallbladder-related issues, such as gallstones (cholelithiasis) or gallbladder inflammation (cholecystitis), may occur. These events are sometimes associated with rapid weight loss. Maintaining hydration and a steady rate of weight loss may help reduce risk.
NOTE: This list may not include all possible adverse reactions or side effects.

Pregnancy
Pregnancy
Tirzepatide is not recommended during pregnancy. Its safety in pregnant individuals has not been established, and it should be avoided unless the potential benefit clearly outweighs any potential risk to the fetus.
Tirzepatide is not appropriate for use in pregnancy for weight management purposes. Weight loss during pregnancy provides no benefit and may be harmful to fetal development.
Individuals who are planning to become pregnant or who become pregnant while using tirzepatide should consult their healthcare provider to explore alternative options for managing blood glucose.
Breastfeeding
The presence of tirzepatide in human breast milk is unknown. This medication should be used with caution during breastfeeding, particularly in mothers of newborns or preterm infants.
The decision to use tirzepatide while lactating should be based on individual factors and made in consultation with a healthcare provider.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond-use date. Do not flush unused medications or pour down a sink or drain.